18F-FDG-PET引导与全肿瘤放疗剂量递增在局部晚期非小细胞肺癌患者中的比较(PET-Boost):一项随机临床试验结果
本研究将不可手术的II-III期非小细胞肺癌患者随机分配至全原发肿瘤剂量递增组或PET定义亚体积剂量递增组,均24次分割。两组1年局部失败自由率分别为97%和91%,均达到主要目标,但两组均出现意外高的5级毒性发生率。
要点
- 全肿瘤组1年局部失败自由率为97%(95%CI 91-100),PET亚体积组为91%(95%CI 82-100)。
- 全肿瘤组急性≥3级不良事件23例(43%),PET亚体积组20例(38%)。
- 全肿瘤组晚期≥3级不良事件12例(22%),PET亚体积组17例(32%);5级事件总计19例(18%)。
核心结论
- 两种剂量递增策略均达到改善1年局部控制的主要目标,但均导致意外高的5级毒性发生率。
- 作者提出剂量分化、改进患者选择和更好地保护中心结构以改善剂量递增策略。
研究设计与样本
- 随机(1:1)II期‘ pick-the-winner’设计临床试验,纳入不可手术的II-III期非小细胞肺癌患者。
- 患者随机接受全原发肿瘤或PET定义亚体积的剂量递增放疗,均24次分割。
- 主要终点为局部失败自由率(FFLF),由CT影像中心审查评估;检验1年FFLF提高15%,α=0.05,β=0.80。
- 150例患者入组,全肿瘤组54例,PET亚体积组53例;因入组缓慢提前关闭。
主要发现
- 全肿瘤组1年FFLF为97%(95%CI 91-100),PET亚体积组为91%(95%CI 82-100)。
- 全肿瘤组急性≥3级不良事件23例(43%),PET亚体积组20例(38%)。
- 全肿瘤组晚期≥3级不良事件12例(22%),PET亚体积组17例(32%)。
- 5级事件总计19例(18%),其中疾病进展前全肿瘤组4例(7%),PET亚体积组5例(9%)。
- 全肿瘤组Boost体积中位剂量/分次为3.30 Gy,PET亚体积组为3.50 Gy。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 试验因入组缓慢提前关闭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We aimed to assess if radiation dose escalation to either the whole primary tumour, or to an 18F-FDG-PET defined subvolume within the primary tumour known to be at high risk of local relapse, could improve local control in patients with locally advanced non-small-cell lung cancer. MATERIALS AND METHODS: Patients with inoperable, stage II-III NSCLC were randomised (1:1) to receive dose-escalated radiotherapy to the whole primary tumour or a PET-defined subvolume, in 24 fractions. The primary endpoint was freedom from local failure (FFLF), assessed by central review of CT-imaging. A phase II 'pick-the-winner' design (alpha = 0.05; beta = 0.80) was applied to detect a 15 % increase in FFLF at 1-year. CLINICALTRIALS: gov:NCT01024829. RESULTS: 150 patients were enrolled. 54 patients were randomised to the whole tumour group and 53 to the PET-subvolume group. The trial was closed early due to slow accrual. Median dose/fraction to the boosted volume was 3.30 Gy in the whole tumour group, and 3.50 Gy in the PET-subvolume group. The 1-year FFLF rate was 97 % (95 %CI 91-100) in whole tumour group, and 91 % (95 %CI 82-100) in the PET-subvolume group. Acute grade ≥ 3 adverse events occurred in 23 (43 %) and 20 (38 %) patients, and late grade ≥ 3 in 12 (22 %) and 17 (32 %), respectively. Grade 5 events occurred in 19 (18 %) patients in total, of which before disease progression in 4 (7 %) in the whole tumour group, and 5 (9 %) in the PET-subvolume group. CONCLUSION: Both strategies met the primary objective to improve local control with 1-year rates. However, both strategies led to unexpected high rates of grade 5 toxicity. Dose differentiation, improved patient selection and better sparing of central structures are proposed to improve dose-escalation strategies.
引用
- Cooke SA, de Ruysscher D, Reymen B, et al. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. Radiother Oncol. 2023. PMID: 36706958. doi:10.1016/j.radonc.2023.109492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。